DTIL
PRECISION BIOSCIENCES INC
NASDAQ · Healthcare · Biotechnology · US
$6.19
+7.28%Year over year
Reported trailing growth
- Revenue
- +3473.0%
- EBITDA
- +32.6%
- EBIT
- +59.6%
- EPS
- +69.6%
- Free cash flow
- +19.3%
- Operating cash flow
- +18.8%
Forward estimates
Based on analyst estimates
- Revenue
- -80.6%
- EBITDA
- +3.2%
- EPS
- +28.7%
Three-year CAGR
- Revenue
- +10.9%
- EBITDA
- —
- EBIT
- -99.3%
- Net income
- —
- EPS
- —
- Free cash flow
- -12.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026